GB2359561A - Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same - Google Patents
Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same Download PDFInfo
- Publication number
- GB2359561A GB2359561A GB0113000A GB0113000A GB2359561A GB 2359561 A GB2359561 A GB 2359561A GB 0113000 A GB0113000 A GB 0113000A GB 0113000 A GB0113000 A GB 0113000A GB 2359561 A GB2359561 A GB 2359561A
- Authority
- GB
- United Kingdom
- Prior art keywords
- lak
- lak activity
- extract
- cells
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000000694 effects Effects 0.000 title claims abstract description 98
- 240000000599 Lentinula edodes Species 0.000 title claims abstract description 79
- 238000002360 preparation method Methods 0.000 title claims abstract description 4
- 230000003389 potentiating effect Effects 0.000 title 1
- 235000001715 Lentinula edodes Nutrition 0.000 claims abstract description 78
- 239000000203 mixture Substances 0.000 claims description 48
- 210000004698 lymphocyte Anatomy 0.000 claims description 41
- 238000009472 formulation Methods 0.000 claims description 40
- 206010028980 Neoplasm Diseases 0.000 claims description 39
- 239000003623 enhancer Substances 0.000 claims description 36
- 210000005259 peripheral blood Anatomy 0.000 claims description 24
- 239000011886 peripheral blood Substances 0.000 claims description 24
- 201000011510 cancer Diseases 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 230000002708 enhancing effect Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002434 immunopotentiative effect Effects 0.000 abstract description 5
- 230000000091 immunopotentiator Effects 0.000 abstract description 4
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 73
- 102000000588 Interleukin-2 Human genes 0.000 description 24
- 108010002350 Interleukin-2 Proteins 0.000 description 24
- 239000002609 medium Substances 0.000 description 24
- 238000010494 dissociation reaction Methods 0.000 description 23
- 230000005593 dissociations Effects 0.000 description 23
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 22
- 239000000243 solution Substances 0.000 description 15
- 239000012091 fetal bovine serum Substances 0.000 description 12
- 239000012980 RPMI-1640 medium Substances 0.000 description 11
- 230000000259 anti-tumor effect Effects 0.000 description 11
- 239000012636 effector Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 8
- 108010001062 polysaccharide-K Proteins 0.000 description 8
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 241000609240 Ambelania acida Species 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 239000010905 bagasse Substances 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 210000000822 natural killer cell Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- -1 immunopotentlators Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000222418 Lentinus Species 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000005965 immune activity Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 241000221198 Basidiomycota Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 108010059892 Cellulase Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000003674 animal food additive Substances 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 229940106157 cellulase Drugs 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 230000004727 humoral immunity Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- FZHXIRIBWMQPQF-UHFFFAOYSA-N Glc-NH2 Natural products O=CC(N)C(O)C(O)C(O)CO FZHXIRIBWMQPQF-UHFFFAOYSA-N 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 208000003623 Hypoalbuminemia Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- 208000006268 Sarcoma 180 Diseases 0.000 description 1
- 241000222481 Schizophyllum commune Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000222355 Trametes versicolor Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000024829 digestive system symptom Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000009313 farming Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 208000018299 prostration Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- PXLIDIMHPNPGMH-UHFFFAOYSA-N sodium chromate Chemical compound [Na+].[Na+].[O-][Cr]([O-])(=O)=O PXLIDIMHPNPGMH-UHFFFAOYSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000000015 thermotherapy Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An immunopotentiator and immunopotentiating preparations which show little side effects and can be obtained economically. An LAK activity potentiator containing a shiitake <I>Cortinellus shiitake</I> mushroom hyphac extract.
Description
2359561 i
SPECIFICATION
LAK ACTIVITY ENHANCERS DERIVED FROM EXTRACT OF LENTINUS EDODES MYCELIUM AND LAK ACTIVITY-ENHANCING FORMULATIONS CONTAINING THE EXTRACT FIELD QF THE INVENTION
The present invention relates to the immunological field. In particular, it relates to immune activity enhancers and therapeutic formulations containing an extract of Lentinus edodes mycelium. And more particularly, it relates to materials useful for enhancing LAK activity and LAK activity-enhancing formulations containing the extract.
PRIOR ART
The activity of the immune system can be classified into two modes of action: Cell-mediated immunity and humoral immunity. Humoral immunity refers to an immune response involving antibodies, while cell-mediated immunity refers to an immune response produced by cells acting 20 directly on a target.
Lymphocytes play the main role in this cell-mediated immune response and often target cell surface substances as antigens. Cell-mediated immunity is thought to be also involved in immune response against tumor, intracellular 25 parasites, and viruses, transplantation, some drug hypersensitivity and some autoimmune diseases. Generally, the reaction is often specific, but can also be non.specific.
1 For example, it is known in tumor immunology that tumor cells possess tumor antigens. That is, it is known that there are two types of antigens, one type consisting of tumorspecific antigens (TSA) and the other of tumor- associated antigens (TAA) which is also present in normal cells at a very low level, and upregulated with malignant transformation.
These tumor antigens are expressed by alteration in a genetic sequence or by mutation of autologous cells. A common therapy used against tumor cells having abnormal antigenic expression is immunotherapy, including immunization with a tumor antigen or administration of a drug which enhances the immune function. It is generally known that natural killer (NK) cells demonstrate higher tumor cell-destroying activity than normal cells and that immunotherapy can also enhance the activity of NK cells. NK cells are cytotoxic lymphocytes also present in normal individuals and are known to exhibit MC antigennonrestricted cytotoxicity against tumor cells, virus- infected cells or the like. However, it has been recently shown that tumor cells exist which are resistant to even NK cells.
Dr. S. Rosenberg of the United States National Cancer Institute (NCI) found that incubation of peripheral lymphocytes with interleukin 2 (IL-2) can induce killer cells showing cytotoxicity to a wide range of target cancer cells, including autologous cancer cells, and that these killer cells can kill even NK cell-resistant cancer cells 2 p c i (see Japanese patent public disclosure No. 116518/87). These killer cells were named lymphokine activated killer (LAK) cells. LAK cells do not consist of a cytologically homogeneous population and are known to include NK cells and killer T-cells.
Recently, adoptive immunity has been attempted wherein peripheral lymphocytes from a patient are activated with IL-2 in a cell culture system, and then LAK cells showing antitumor activity are reinfused into the patient (LAK therapy). It has been reported that remission from terminal cancer has been achieved or tumor growth-inhibited by the use of adoptive immunotherapy involving repeated administration of such LAK cells. However, IL-2-mediated LAK therapy involves a number of problems such as the physical stress associated with the isolation of a great number of leukocytes, the high cost of performing mass culture of isolated leukocytes, or the use of expensive IL2, etc, and, moreover, IL-2 administration often causes serious side effects.
Specifically, it is known that LAK adoptive immunotherapy using IL-2 causes side effects such as general prostration, chills, fever, hypoalbuminemia, anemia, eosinophilia and that these side effects are more serious than those caused by administration of IL-2 alone. More notably, some important side effects are strongly associated with the cytotoxicity of LAK cells against normal cells. It is also reported that such cytotoxicity of LAK cells against hematopoietic stem cells induces 3 - t # 1 f anemia and thrombocytopenia, as well as causing in vitro damages to lymphocytes, macrophages and vascular endothelial cells. Moreover, IL-2 administered via the oral route is poorly absorbed and must therefore mainly be administered via injection and direct administration at the present time.
Thus, there is a demand for the development of therapeutic agents capable of overcoming these disadvantages, especially agents that could enhance the LAK activity of lymphocytes without using IL-2 or pharmaceutical agents containing such agents.
Anticancer agents are generally targeted at abnormal growth of cancer cells and can be classified by target into nucleic acid biosynthesis inhibitors such as alkylating agents, nucleic acid biosynthesis substrate analogs, antibiotics, steroid hormones, etc. and mitotic inhibitors such as plant alkaloids.
However, such anticancer agents also cause noticeable side effects with regard to normal proliferative cells such as bone marrow, gastrointestinal epithelium, and hair follicle. That is, they generally cause nausea, vomiting, ulcers of the mouth and small bowel, diarrhea, epilation, bone marrow inhibition leading to underproduction of major blood components, and so on, irrespective of the administration route.
Some bacteria, foods and other naturally occurring substances are known to have anticancer properties. Bacteria and food-tye substance are generally far 4 - ? i preferential for use as anti-cancer agents due to their generally benign nature and low side-effect profile. Many attempts have been made to cure cancer by using bacteria as shown in reports relating to Coley's toxin consisting of a culture filtrate of Serratia marcesens and Streptococcus pyogenes (1964); treatment of leukemia with BW (Mathe, G., Adv. Cancer Res., 14, 1, 1971); tumor regression in guinea pigs (Zbar, B_ et al., J. Natl. Cancer Inst., 48, 831, 1971); and effectiveness of administration of yeast cell wall polysaccharide against transplanted tumor cells such as sarcoma 180, for example.
Especially, a great amount of research has been conducted into the anticancer effect of polysaccharides derived from yeast such as yeast glucan and yeast mannan, from other bacteirum, from lichens and from basidiomycetes. Among them, commercial products currently available on the market as anticancer immunopotentiators include Krestin derived from the cultured mycelia of kawaratake (Coriolus versicolor, Basidiomycetes: Polyporaceae) (booster of immune function of hosts, Kureha Chemical Industry and Sankyo Co.Ltd.), a polysaccharide derived from shlitake (Lentinus edodes) called lentinan and a polysaccharide derived from suehirotake (Schizophyllum Commune).
Lentinus edodes (Shiitake) is a common edible mushroom found in both Japan and China, and has been cultivated in Japan for around 300 years. It has been recently elucidated for its pharmacological effects and effective ingredients and reported to have various effects, 1 such as growth inhibition effects on transplanted tumor cells in the large bowel and liver in rats and mice (Sugano N. et al., Cancer Letter, 27:1, 1985; Suzuki Y. et al., Journal of the Japan Society of Coloproctology, 43:178, 5 1990); mitogenic effect (Tabata T. et al., Immunopharmacology, 24:57, 1992; Hibino et al., Immunopharmacology, 28:77, 1994), etc.
DISCLOSURE OF THE INVENTION
The present inventors researched the immunopotentiating activity, antitumor activity and/or anticancer activity of Lentinus edodes with a view to providing an inexpensive immunotherapeutic agent having few side effects.
The present invention was accomplished on the basis of the finding that an extract of the mycelium, which is a precursor to the edible fruiting body of Lentinus edodes, has a far higher immunopotentiating activity, antitumor activity and/or anticancer activity than the fruiting body and that said extract also has an LAK activity-enhancing activity.
According to the first aspect of the present invention, therefore, an LAK activity enhancer containing an extract of Lentinus edodes mycelium is provided.
"LAK activity" refers to the cytotoxic activity of cytotoxic T-lymphocytes, which attacks tumors unrecognizable by lymphocytes having NK activity but which have little influence on autologous normal cells. "LAK 6 - 1 activlty-enhancing" refers to the effect of enhancing this LAK activity, that is directly or indirectly inducing the production of LAK cells from lymphocytes or further enhancing the activity of existing LAK cells.
Enhancement of LAK activity increases antitumor activity of LAK cells, which leads to an improvement in the function of the cell-mediated immune system. Thus, the present invention can be applied not only to treatments for improving antitumor activity but also to treatments for improving the immune function.
Lymphocytes derived from peripheral blood may be treated with LAK activity enhancers of the present invention to enhance LAK activity. They may directly act on lymphocytes derived from peripheral blood preferably at an extract of Lentinus edodes mycelium. concentration of 1 ptg or more per 106 lymphocytes or 1 ptg or more per 1 ml of peripheral blood. LAK activity enhancers of the present invention may be used in LAK therapy in place of IL-2.
LAK activity enhancers of the present invention may consist of an extract of Lentinus edodes mycelium on its own or may further contain materials other than an extract of Lentinus edodes mycelium. The range of such materials is not limited so long as the LAK activity enhancingactivity of the extract of Lentinus edodes mycelium is not affected by their use.
LAK activity enhancers of the present invention may also be combined with other materials having an immunopotentiating activity and antitumor activity and/or anticancer activity.
According to the second aspect of the present invention, an LAK activityenhancing formulation comprising an LAK activity enhancer containing an extract of Lentinus 5 edodes mycelium is provided.
LAK activity-enhancing formulations of the present invention may be the extract of Lentinus edodes mycelium itself or pharmaceutical or veterinary formulations comprising an LAK activity enhancer containing an extract of Lentinus edodes mycelium and a pharmaceutically acceptable carrier.
LAK activity-enhancing formulations of the present invention may be suitable for oral administration or injection LAK or percutaneous administration. activity-enhancing formulations of the present invention may be in the form of a food, drink or feed.
LAK activity-enhancing formulations of the present invention may be used for treating tumor and/or cancer. LAK activity-enhancing formulations of the present invention do not specifically attack specific tumor cells, because they induce LAK cells. Therefore, LAK activity enhancing formulations of the present invention can be used for treating various tumors, either epithelial or non epithelial.
LAK activity-enhancing formulations of the present invention may also be used for treating other diseases than tumor or cancer, such as the improvement of the immune function. Specifically, LAK activity-enhancing j formulations of the present invention may also be used for the improvement of immune function compromised by immunocompromising therapies or accidents such as radiation, autoimmune diseases, infectious diseases, etc.
LAK activity-enhancing formulations of the present invention can also be used as prophylactic agents against various diseases. For example, they may be administered to prevent tumor and/or cancer or to prevent bacterial or viral infections.
LAK activityenhancing formulations of the present invention may be used in combination with other drugs such as antitumor and/or anticancer agents such as immunopotentlators, antibiotics, analgesics, antiinflammatory agents, etc.
According to the third aspect of the present invention, a method for treating tumor and/or cancer comprising administering an effective amount of said LAK activity-enhancing formulation is provided.
The method for treating tumor and/or cancer of the present invention may be used in combination with other therapies such as other chemotherapy, surgical treatment, radiation, thermotherapy, etc.
According to the fourth aspect of the present invention, a use of an LAK activity enhancer for obtaining a drug used for treating tumor and/or cancer is provided.
In order to obtain a drug used for treating tumor and/or cancer, LAK activity enhancers of the present invention may be used in combination with other materials 9 - 1 1 t 1 having an immunopotentiating activity and antitumor activity and/or anticancer activity.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a bar graph showing the LAK activityenhancing effect of the extract of Lentinus edodes mycelium directly added to peripheral blood as in comparison with IL-2.
FIG. 2 is a bar graph showing the change of LAK activity with the concentration of the extract of Lentinus edodes mycelium directly added to peripheral blood.
FIG. 3 is a bar graph showing the LAK activity obtained by directly adding Krestin to peripheral blood.
FIG. 4 is a bar graph showing the LAK activity in peripheral blood before and after oral administration of the extract of Lentinus edodes mycelium.
THE MOST PREFERRED EMBODIMENTS OF THE INVENTIO An extract of Lentinus edodes mycellum contained in LAK activity enhancers of the present invention refers to an extract obtained by crushing and decomposing mycelia grown from Lentinus edodes cultured on a solid medium, or a solid medium itself containing Lentinus edodes mycelia in the presence of water and an enzyme. 25 An extract of Lentinus edodes mycelium used herein is preferably obtained by, but not specifically limited to, the following process. Lentinus edodes spawn is inoculated on a solid medium - 1 1 i based on bagasse (sugar cane residue) and defatted rice bran to grow mycelia, and then the solid medium containing the grown mycelia is delignified to enable about 30% by weight or less to pass through a 12-mesh sieve.
5. To this delignified solid medium are added water and one or more enzymes selected from cellulase, protease or glucosidase while maintaining said solid medium at a temperature of around 30-550C, and said solid medium is crushed and ground in the presence of said enzyme so that at least 70% by weight of bagasse fiber is able to pass through a 12-mesh sieve. Then, the temperature is raised to 80-1000C to ensure inactivation of the enzyme and sterilization, and the resulting suspension is filtered to give an extract of Lentinus edodes mycelium.
The extract of Lentinus edodes mycelium as prepared above may be directly used in LAK activity enhancers or LAK activity-enhancing formulations of the present invention, but conveniently concentrated and freeze-dried into powder to be stored and used in various forms. The freeze-dried product is a brown powder with hygroscopic characteristics and has a peculiar taste and odor.
LAK activity enhancers containing the prepared extract of Lentinus edodes mycelium (or the extract of Lentinus edodes mycellum on its own) may be used in LAK therapy in place of IL-2 to enhance the immune activity against tumor of the subject.
LAK therapy generally comprises the steps of culturing in vitro lymphocytes from the subject with IL-2 1 to induce LAK cells from the lymphocytes, and reinfusing the LAK cells into the subject. At the step of reinfusing LAK cells into the subject, IL-2 may be (directly) cocurrently administered.
LAK activity enhancers containing the extract of Lentinus edodes mycelium. of the present invention may be cultured in vitro with lymphocytes from the subject (human, animals, etc.) to induce LAK cells or may be (directly) cocurrently administered to the subject at the step of reInfusing the cultured lymphocytes to the subject. They may be used in combination with other antitumor and/or anticancer agents.
LAK activity enhancers containing the extract of Lentinus edodes mycelium of the present invention may be directly added to peripheral blood collected from the subject, but preferably sterilized with acetone before being added.
LAK activity enhancers containing the extract of Lentinus edodes mycelium of the present invention can be directly added to peripheral blood collected from the subject preferably at a concentration expressed as the extract of Lentinus edodes mycelium of 1 Rg - 1 Mg/106 lymphocytes, more preferably 10 ig - 100 ptg/10' lymphocytes, most preferably 10 Rg.Rg/106 lymphocytes. The dose per ml of peripheral blood, which partially depends on the level of lymphocytes in peripheral blood, approximately represents 1 Rg 2.5 mg, preferably 10 tg - 250 Rg, more preferably 10 Rg 125 Rg.
12 - 11 r 1 t LAK activity-enhancing formulations comprising an LAK activity enhancer containing the extract of Lentinus edodes mycelium of the present invention can be directly administered to the subject to enhance the anti- tumor immune activity of the subject, thereby providing an effect comparable to the effect elicited by LAK therapy using IL-2.
Induction of LAK cells in the subject such as a human or animals by directly administering the LAK activity enhancers of the present invention may make it possible to reduce physical stress associated with the isolation of a great number of leukocytes and the high cost resulting from producing mass culture. In addition, the use of LAK activity-enhancers of the present invention can also reduce the risk of contamination during the isolation of blood from the subject and reinfusion can also be reduced.
LAK activity-enhancing formulations of the present invention are administered most preferably, but.are not limited to, the oral route in view of the least stress imposed on the subject and the like. They may also be administered via intravenous, intracutaneous, subcutaneous or intramuscular injection, or percutaneous, nasal, enteral or other routes.
Suitable dosage forms of LAK activity-enhanc ng formulations of the present invention include, but are not limited to, tablets, capsules, powders, granules, solutions, syrups, injections, creams, ointments, patches, sprays, suppositories, etc.
Pharmaceutically acceptable carriers that can be 13 - 1 optionally mixed with LAK activity-enhancing formulations of the present invention include, but not limited to, excipients such as lactose, dextrose, starch, crystalline cellulose; binders such as starch, gelatin, methyl cellulose, polyvinylpyrrolidone; disintegrators such as starch, calcium carboxymethylcellulose, carboxymethyl starch; lubricants such as talc, stearates; coating agents. such as sucrose, talc, gelatin; as well as various brighteners, flavoring agents, colorants, corrigents, solubilizers, stabilizers, suspending agents, absorbefacients or the like known in the art depending on the purpose. For use as injections, various diluents commonly used in this field of art such as water or ethyl alcohol can be used.
The route of administration, dose, frequency or others of LAK activityenhancing formulations of the present invention are determined taking into account the age, weight, condition and other factors of the subject.
The extract of Lentinus edodes mycelium contained in LAK activity-enhancing formulations of the present invention is highly safe as has been traditionally ingested as a component of food. Therefore, the dose is not be strictly limited. For example, the extract of Lentinus edodes mycelium is normally administered preferably at a dose of 100 mg 10000 mg 2-3 times daily, more preferably 500 mg - 5000 mg three times daily, most preferably 1000 mg ---1500 mg three times daily. It may be administered in combination with other drugs such as antitumor and/or 14 t anticancer agents such as immunopotentiators, antibiotics, analgesics, antiinflammatory agents, etc.
LAK activity-enhancing formulations of the present invention can also be provided in the form of a food. Preferred forms of food include powders, granules, pastes, jellies, etc. Granules desirably are supplemented with sugars such as lactose to add a sweet taste. LAK activityenhancing formulations of the present invention can also be provided in the form of a drink. These foods or drinks may be supplemented with vitamins, minerals such as calcium, alcohols, deodorants such as polyphenols in addition to the extract of Lentinus edodes mycelium. These foods or drinks may include the categories of specific health foods, medical foods or the like.
LAK activity-enhancing formulations of the present invention can also be provided in the form of a feed or feed additive. LAK activity-enhancing formulations of the present invention can be used as a feed or feed additive for domestic animals to treat and/or prevent tumor occurring in the domestic animals or to treat and/or prevent bacterial or viral infections in domestic animals.
As a result, the amount of therapeutic agents such as antibiotics currently used can be reduced, thereby reducing farming costs. Another advantage is that the period during which shipment of animals is suspended due to the administration of antibiotics can be shortened.
LAK activity enhancement with LAK activity enhancers of the present invention can be confirmed by, but not - f 1 1 limited to, the procedure below according to the method of Takagi et al. (Clinical Immunology, 19:245-249, 1987).
LAK activity test LAK activity can be determined by 51Cr release assay, [3 H] uridine assay or the like. In terms of convenience and objectivity, the '51Cr release assay is preferably used.
The 51Cr release assay is one of methods for in vitro determining the cytotoxicity against target cells of LAK cells induced from lymphocytes treated with an LAK activity enhancer, and comprises the steps of:
(i) adding 5'Cr-labeled sodium chromate to the target cells to label the target cells, (ii) reacting the labeled target cells with induced LAK cells, and (Iii) measuring the amount of -51Cr released into the cell culture supernatant from the target cells bursted by the LAK cells.
Subcultured cells used as target cells in the 51Cr release assay are preferably Daudi cells or Raji cells. Target cells cultured in a culture flask or the like are collected by centrifugation, and labeled with "Cr via incubation in a 5% C02 incubator at 370C for 1-2 hours after 100-150 iCi 51Cr labeled-sodium chromate has been added. Culture media for target cells are those suitable for the growth of the cells used, and include, for example, liquid media such as RPMI 1640 or F- 12 appropriately supplemented with serum, antibiotics, etc.
1 - Cultured target cells are washed with PBS three times, and then suspended in a culture medium at a density of 1 x 106 Cel1S/M1 to serve for assay.
To induce LAK cells, lymphocytes are isolated from peripheral blood of the subject. Heparin is added to peripheral blood from the subject, and monocytes at the interface are separated by density gradient centrifugation on Ficoll-Conray solution (s.g. = 1.077). The separated monocytes are washed with PBS (pH 7.4, without Ca and Mg) 2-3 times and then suspended in a culture medium (preferably, RPMI 1640 medium (Gibco) containing FBS (inactivated fetal bovine serum) and/or antibiotics, if desired) at a density of 1 X 106 cells /ml. This suspension is transferred to a Petri dish which has been precoated with autoserum (plasma) at 370C f or 15 minutes, and incubated at 370C for 1 hour. Unattached cells are recovered as lymphocyte fractions.
The lymphocytes as prepared above are suspended in a culture medium at a predetermined concentration, preferably 1 X 10-5_106 cells/ml.
The extract of Lentinus edodes mycelium is added to the medium as used for preparing the lymphocyte-suspending solution at a final concentration of about 1-100 lig/ml.
Predetermined amounts of the lymphocyte-suspending solution and extract-containing medium are added to wells of a culture plate. In parallel, predetermined amounts of the lymphocyte-floating solution and the medium not containing the extract of Lentinus edodes mycelium are 17 r added to wells as an extract-free control. Then, the culture plate is statically incubated in a C02 incubator at room temperature for 3 days.
When a 96-well U-bottom microtest plate is used, for example, 100 R1 of the lymphocyte-floating solution is preferably added to each well at a density of 1 X 104 to 1 x 105 cells/well. The number of cells per well can be appropriately determined by those skilled in the art in accordance with the well volume, the activity of LAK cells, the sensitivity of target cells to LAK cells, etc.
Thus, lymphocytes derived from the subject are cultured in the presence of the extract of Lentinus edodes mycelium of the present invention at various concentrations (including zero) to induce effector cells. As used herein, the term effector cells refers to cells subjected to said culture treatment for 3 days and includes both lymphocytes cocultured with an LAK activity enhancer (lymphocytes treated with an LAK activity enhancer) and lymphocytes cultured in the medium alone without LAK activity enhancer (lymphocytes treated under the extract-free condition).
Cultured lymphocytes (effector cells) are recovered from the well and resuspended in fresh RPMI 1640 medium containing 10% FBS (1 X 106 cells/ml).
In the assay for determining cytotoxicity, each well containing said target cells is further supplied with a predetermined amount of the floating solution containing said various effector cells (lymphocytes treated with LAK active enhancer or those under the extract- free condition) 18 - p 41 at a density of 1 x 105 - 1 x 106 cells/ml for experimental dissociation, 1N HCl in an amount equal to the effectorfloating solution for maximum dissociation, or the medium alone in an amount equal to the effector- floating solution for natural dissociation. Then, cells are collected at the bottom of the well of the culture plate using a plate centrifuge or the like, and then incubated in a 5% CO, incubator at 370C for a predetermined period (for example, 2-5 hours).
After completion of the incubation, the radioactivity O.L Cr released in the culture supernatant in the culture supernatant in each well is measured using a scintillation counter or the like.
The term "maximum dissociation" refers to the total amount of 5'Cr released when all the target cells are destroyed. Maximum dissociation can be determined by, for example, lysing target cells via incubation in a culture medium containing 1N HCl under predetermined conditions in the absence of effector cells and measuring the amount of -"Cr released in the culture supernatant.
The term "experimental dissociation" refers to the amount of 51 Cr released by cytotoxicity of effector cells against target cells and natural death of target cells when effector cells are added to target cells. Experimental dissociation can be determined by, for example, incubating target cells under the same conditions as those for maximum dissociation with the exception of adding effector cells in place of 1N HCl to the culture medium and measuring the amount of 51Cr released in the culture supernatant.
The term "natural dissociation" refers to the amount of-"Cr released by natural death of target cells.Natural dissociation can be determined by, for example, incubating target cells under the same conditions as for maximum dissociation with exception of containing neither 1N HCl nor effector cells and measuring the amount of 51Cr released in the culture supernatant.
The activation level of LAK cells is evaluated on the 10 basis of the LAK activity calculated by equation (1) below.
Experimental dissoc ation(cpm)-Natural dissociation(cpm) Maximum dissociation(cpm)-Natural dissociation(cpm) Equation (1) LAK activity% = X 100 The disclosure of JPA Nos. 353927/98 and 353928/98 on which thepresent application is based to claim the priority are incorporated herein as a whole as reference.
The following examples further illustrate the present invention but should not be taken as limiting the scope of the invention thereto. It will be appreciated by those skilled in the art that various changes and modifications can be made without departing from the spirit of the present invention.
EXAMPLES Example 1: Preparation of an extract of Lentinus Cdodes myceliu A solid medium consisting of 90 parts by weight of 20 bagasse and 10 parts by weight of rice bran was soaked with an appropriate amount of pure water, and then inoculated with Lentinus edodes spawn and allowed to stand in an incubator at controlled temperature and humidity to grow mycelia. After mycelia spread over the solid medium, the bagasse base was delignified to enable 24% by weight or less eto pass through a 12-mesh sieve. To 1.0 kg of this delignified medium were added 3.5 L of pure water and 2.0 g of purified cellulase while maintaining the solid medium at 400C to prepare a medium-containing mixture.
Then, the medium-containing mixture was circulated by a variable speed gear pump, during which the solid medium was crushed and ground at the gears for about 200 minutes so that about 80% by weight of bagasse fiber is able to pass through a 12-mesh sieve. The medium-containing mixture was crushed and ground while the temperature of said mixture was gradually increased. Then, the medium containing mixture was further heated to 900C to ensure inactivation of the enzyme and sterilization and allowed to stand at 900C for 30 minutes. The resulting medium containing mixture was filtered through a 60-mesh filter cloth to give an extract of Lentinus edodes mycelium solution, which was concentrated and then converted into a freeze-dried powder.
The extract of Lentinus edodes mycelium, as prepared above contained 25.3% (wlw) carbohydrates determined by the phenol-sulfuric acid method, 19.7% (w/w) proteins determined by the Lowry method and 2.6% (w/w) polyphenols I. k.
determined by the Folin-Denis method using gallic acid as standard. The extract of Lentinus edodes mycelium further contains 8% crude fat, 22% crude ash and about 20% soluble nitrogen-free materials other than carbohydrates.
The extract of Lentinus edodes mycelium had a sugar composition (%) as follows: Xyl 15.2, Ara 8.2, Man 8.4, Gul 39.4, Gal 5.4, GlcN 12.0, GluUA 11.3.
Example 2: Comparison of LAK activities of the extract of Lentinus edodes mycelium and IL-2 The extract of Lentinus edodes mycelium obtained in Example 1 was directly administred to peripheral blood collected from the subject to compare the LAK activity enhancing effect with that of IL-2.
Heparin was added to peripheral blood from subject A, and monocytes at the interface were separated by density gradient centrifugation on Ficoll-Conray solution (s.g.
1.077). The separated monocytes were washed with PBS (pH 7.4, without Ca and M9) twice and then suspended in RPMI 1640 medium (Gibco) containing 10% FBS (inactivated fetal bovine serum) at a density of 1 X 106 cells /ml. This cell suspension was transferred to a Petri dish which had been precoated with autoserum (plasma) at 370C for 5 minutes followed by incubation at 370C for 1 hour, and then unattached cells were recovered as lymphocyte fractions.
The lymphocytes as prepared above were suspended in RPMI 1640 medium (G1bco) containing 10% FBS (inactivated serum) at 1 X 106 cells /ml.
22 k LAK activity enhancer-containing solutions were prepared by adding IL-2 at a final concentration of 25 U/ml or the extract of Lentinus edodes mycelium obtained in Example 1 at final concentrations of 1, 10, 100 or 1000 Rg/ml to RPMI 1640 medium (Gibco) containing 10% FBS (inactivated serum).
To each well of a 96-well U-bottom microtest plate were added 100 R1 of the lymphocyte-suspending solution and 100 R1 of IL-2 or the LAK activity enhancer-containing solution containing the extract of Lentinus edodes mycelium at various concentrations (a total of 200 R1). As an extract-free control, 100 R1 of the lymphocytesuspending solution and 100 R1 of the extract-free medium (RPMI 1640 medium (Gibco) containing 10% FBS (inactivated serum)) were added. Then, the culture plate was statically incubated in a C02 incubator at room temperature for 3 days.
Cultured lymphocytes (effector cells) were recovered from the well and resuspended in fresh RPMI 1640 medium containing 10% FBS at a concentration of 1 X 106 cells/ml.
Target cells (Daudi cells from Dainippon Pharmaceutical) subcultured in RPMI 1640 medium containing 10% FBS were recovered by centrifugation, and incubated with 100-150 RCi/106 cells of 51Cr labeled-sodium chromate (New England Nuclear) in a 5% C02 incubator at 370C for 1 hour. Cultured cells labeled with -"Cr were washed with PBS three times, and then suspended in RPMI 1640 medium containing 10% FBS at a concentration of 1 X 106 cells/ml.
A 50 R1 aliquot (5 x 104 cells/well) of labeled - 23 target cells was added to each of wells of the microtest plate for maximum dissociation, natural dissociation and experimental dissociation. In addition, 100 P1 of 1N HCl was added to each well for maximum dissociation, 100 91 of RPMI 1640 medium containing 10% FBS was added to each well for natural dissociation, and 100 91 of effector cells treated with 10 P9/ml of the extract of Lentinus edodes mycelium of the present invention at concentrations of 1, 10, 100 and 1000 Pg/m1 or 25 U/m1 of IL -2 or the medium alone were added to each well for experimental dissociation. Here, each well for experimental dissociation, maximum dissociation and natural dissociation was not located around the outer periphery of the plate.
Then, the microtest plate was centrifuged at 800 rpm for 5 minutes on a plate centrifuge to collect cells at the bottom of the well, and then incubated in a 5% CO, incubator at 370C for 3,5 hours.
The culture supernatant in each well was collected by SOKEN-PET E-96 from the incubated plate, and the radioactivity was measured in a Y-scintillation counter.
LAK activity was calculated by equation (1) above.
The results are shown in Table 1 and Fig. 1.
Table 1
Test No. Inducer LAK activity 1 None 11% 2 IL-2 (final concentration: 25 U/mi) 55% 3 Extract of Lentinus edodes mycelium 14% (final concentration: 1 Rg/m1) 4 Extract of Lentinus edodes mycelium 20% (final concentration: 10 Rg/m1) Extract of Lentinus edodes mycelium 14% (final concentration: 100 Rg/m1) In order to examine the toxicity of the extract of Lentinus edodes mycelium to lymphocytes, lymphocytes was treated with the extract of Lentinus edodes mycelium. as prepared In Example 1 at a final concentration of 1 mglml by the same procedure as described above and observed under a microscope to show that almost 100% of lymphocytes survived (data not shown).
Example 3: Optimal concentration of the extract of Lentinus cdodes mycelium for LAK activity The optimal concentration of the extract of Lentinus edodes mycelium to be directly added to peripheral blood collected from the subject was examined. LAK activity was calculated in the same manner as described in Example 2 with exception that the extract of Lentinus edodes mycelium as prepared in Example 1 was added at final concentrations of 1, 5, 10 and 100 RgIml to peripheral blood collected 1 from subjects B and C.
The results are shown in Table 2 and Fig. 2.
As shown in Table 2 and Fig. 2, the extract of Lentinus edodes mycelium of the present invention shows th highest LAK activity when it is added at a final concentration of 10 Rg/ml or 50 R9/ml (i.e. 10 tg or 50 Rg per 106 lymphocytes). The dose-to peripheral blood also depends on the proportion of lymphocytes in peripheral blood of the subject, but approximately corresponds to about 10-25 Rg or 50-125 Rg of the extract of Lentinus edodes mycelium per 1 ml of peripheral blood.
Table.2
Test No. Inducer LAK activity Subject B C 1 None 13% 27% 2 Extract of Lentinus edodes mycelium 18% 28% (final concentration: 1 lig/ml) 3 Extract of Lentinus edodes mycelium 19% 29% (final concentration: 5 Rg/m1) 4 Extract of Lentinus edodes myeelium 21% 34% (final concentration: 10 Rg/m1) Extract of Lentinus edodes mycelium 19% 36% (final concentration: 50 R9/m1) 6 Extract of Lentinus edodes mycelium 15% 30% (final concentration: 100 Rg/m1) 26 r P CQ=arative example 1: LAK activity Qf Krestin LAK activity-enhancing effect of an immunopotentiator Krestin was examined to compare it with the effect of the extract of Lentinus edodes mycelium of the present invention. LAK activity-enhancing effect of Krestin was evaluated in the same manner as described in Example 2 with exception that Krestin (from Kureha Chemical Industry) was added to peripheral blood collected from subject D at a f inal concentration of 1 mg/ml.
The final concentration of 1 mg/ml is the concentration said to be the most effective when Krestin is used to induce LAK cells.
The results are shown in Table 3 and Fig. 3.
As shown in Table 3 and Fig. 3. the LAK-enhancing activity of Krestin was lower than that of a control not containing LAK activity enhancer even at the optimal concentration of 1 mg/ml.
Table 3
Test No. Inducer LAK activity 1 None 14% 2 Krestin (final concentration: 1 mg/ml) 13% Example 4: Determination of LAK activity before and afte administration of a formulation containina the extract of Lentinus edodes myceliu An LAK activity-enhancing formulation containing the 25 extract of Lentinus edodes mycelium prepared in the same 27 - p manner as described in Example 1 was administered to subjects B, C, E and F to evaluate the LAK activityenhancing effect.
This LAK activity-enhancing formulation comprises 0.6 g of the extract of Lentinus edodes mycelium. and 2.4 g of lactose per 3 9 of the formulation, and was administered at a dose of 6 9 (1.2 g as the extract of Lentinus edodes mycelium) three times daily or a total of 3.6 g/day expressed as the extract of Lentinus edodes mycelium for a week. Peripheral blood was collected from each subject before administration and about 2 hours after the final.administration, and LAK activity was determined in the same manner as described in Example 2.
The results are shown in Table 4 and Fig. 4.
As shown in Table 4 and Fig. 4, the extract of Lentinus edodes mycelium of the present invention remarkably increased LAK activity in all of subjects B, C, E and F.
Table 4
Subject Before administration of LEM After administration of LEM LAK activity B C 27% E F 13% 14% 18% 40% 43% 18% 28% In order to examine side effects caused by the administration of the extract of Lentinus edodes mycelium, biochemical blood tests were performed on subjects B, C and 28 ? E. The results are shown in Table 5. Throughout the period for administration of the extract of Lentinus edodes mycellum, subjects B, C, E and F did not show any side effects, such as generalized fatigue, chills, fever or 5 digestive system symptoms.
As also shown in Table 5, any side effects were not observed by administration of the extract of Lentinus edodes mycelium of the present invention.
29 - 1 Table 5
Subject B Subject C Subject E Administration for 1 week Before After Before After Before After WBC (X103/11) 5.45 5.94 5.85 5.08 8.01 7.47 RBC (x10'1tl) 4.56 4.61 4.99 4.85 4.89 4.65 Hb (g/dl) 14.2 14.2 14.4 13.8 15.5 14.8 Ht (%) 42.2 42.8 43.6 42.1 44.8 42.9 MCV (fl) 92.5 92.8 87.4 86.8 91.6 92.3 MCH (pq) 31.1 30.8 28.9 28.5 31.7 31.8 MCHC (g/dl) 33.6 33.2 33.0 32.8 34.6 34.5 PLT (x10'JR1) 19.1 18.5 23.9 19.3 29.2 29.7 RDW-SD (fl) 43.7 44.6 43.5 43.6 43.7 44.8 RM-CV (%) 12.8 13.0 13.4 13.6 13.0 13.3 PDW (fl) 14.0 13.4 11.6 12.6 13.3 13.2 MPV (fl) 11.1 10.9 10.0 10.2 10.6 10.4 P-LCR 34.1 32.5 24.9 27.6 30.1 28.8 Stab 0.5 0.5 1.0 0.0 0.5 0.0 Seg 54.0 48.5 56.0 43.5 46.5 38.5 Lym 37.5 40.5 38.0 43.5 28.5 35.0 Mono 4.5 7.5 3.0 9.5 11.5 8.5 E0 2.5 3.0 1.5 1.0 12.0 15.5 Baso 1.0 0.0 0.5 0.5 0.5 0.5 TP (g/dl) 6.6 6.9 7.7 7.5 8.0 7.7 ALB (gldl) 3.9 4.1 4.4 4.3 4.8 4.7 A/G 1.44 1.46 1.33 1.34 1.50 1.57 TTT (SHU) 3.9 5.0 8.0 8.1 5.3 3.0 ZTT (Kunk) 8.6 8.4 12.6 12.4 6.3 4.9 U-N (mg/dl) 10.4 10.3 10.2 11.2 11.8 11.6 U-A (mg/dl) 5.6 5.9 5.4 5.2 6.1 5.9 Creati-nine (mg/dl) 0.67 0.71 0.84 0.82 0.67 0.72 Overall BIL (mgldl) 0.6 0.7 0.5 0.6 0.5 0.5 Direct BIL (mgldl) 0.1 0.1 0.0 0.0 0.1 0.1 Indirect BIL (mgldl) 0.5 0.6 0.5 0.6 0.4 0.4 GLU (mgldl) 124 104 94 ill 115 114 AST (GOT) (IU/1) is 13 16 16 33 33 ALT (GPT) (1UJ1) 29 30 20 20 45 57 LD (LDH) (IU/1) 142 139 171 152 380 343 CK (CPK) (IU/1) 121 131 227 177 317 224 ALP (IU/1) 131 136 156 148 174 162 Y-GT (IU/1) 12 14 23 23 225 240 LAP (IU/1) 45 40 80 73 134 120 CHE (IU/1) 2358 2593 2779 2749 3191 3299 ANY (IUII) 78 87 107 93 59 54 T-CHO (mg/dl) 208 232 206 200 255 243 HMCHO (mgldl) so 50 44 40 47 47 T-G (mg/dl) 135 210 270 303 451 359 Na (mEq/1) 141 142 140 141 139 141 K (mEq/1) 3.7 3.9 4.1 3.8 4.0 4.2 Cl (mEq/1) 106 107 105 107 103 104 Ca (mEq/1) 4.4 4.4 4.6 4.4 4.9 4.7 I-P (mg/dl) 3.3 3.1 3.0 2.7 3.5 3.2 H 0 0 0 0 1 0 L 0 0 0 1 1 0 1 0 RA test CRP (mg/dl) 0.03 0.06 0.02 0.01 0.07 0.12 ANA <40 <40 <40 <40 <40 <40 ANA pattern CH50 (CH50/m1) 33.0 33.0 45.0 42.0 53.0 52.0 INDUSTRIAL APPLICABILIT LAK enhancers containing the extract of Lentinus edodes mycelium of the present invention showed similar effects to those of IL-2 with no direct toxicity to lymphocytes when they were directly administered to peripheral blood. They are available at far lower cost as compared with IL-2. Therefore, they can be substituted for expensive IL-2 which also has the disadvantage of causing strong side effects.
Formulations containing the extract of Lentinus edodes mycellum of the present invention could remarkably increase LAK activity with no side effects even by direct administration. Therefore, formulations containing the extract of Lentinus edodes mycelium of the present invention are useful as an immunopotentlator capable of increasing LAK activity with a benign side-effect profile by direct administration such as oral administration without using LAK therapy.
- 31 t 1 1 1.
Claims (11)
1. An LAK activity enhancer containing an extract of Lentinus edodes mycelium.
2. The LAK activity enhancer of claim 1 for enhancing LAK activity by acting on lymphocytes derived from peripheral blood.
3. The LAK activity enhancer of claim 2 containing an extract of Lentinus edodes mycelium at a concentration of 1 ptg or more per 10' lymphocytes.
4. An LAK activity-enhancing formulation containing the LAK activity enhancer of claim 1.
5. A pharmaceutical or veterinary LAK activityenhancing formulation comprising the LAK activity enhancer of claim 1 and a pharmaceutically acceptable carrier.
6. The LAK activity-enhancing formulation of claim 4 or 5 for oral administration.
7. The LAK activity-enhancing formulation of claim 4 in the form of a food, drink or feed.
8. The LAK activity-enhancing formulation of claim 4 or 5 for injection or percutaneous administration.
9. The LAK activity-enhancing formulation of any one of claims 4 to 8, wherein said formulation is used for treating tumor and/or cancer.
10. A method for treating tumor and/or cancer comprising administering an effective amount of the LAK activity-enhancing formulation of any one of claims 4 to 8.
11. A use of the LAK activity enhancer of claim 1 for the preparation of a drug used for treating tumor and/or 32 - f 1 1 cancer.
c
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10353928A JP2000159686A (en) | 1998-11-27 | 1998-11-27 | Preparation for lak activity potentiation arising from extract from mycelia of lntinus edodes |
| JP10353927A JP2000159685A (en) | 1998-11-27 | 1998-11-27 | Lak activity potentiator arising from extract from mycelia of lentinus edodes |
| PCT/JP1999/006616 WO2000032212A1 (en) | 1998-11-27 | 1999-11-26 | Lak activity potentiator orginating in shiitake mushroom hyphae extract and lak activity potentiating preparations containing the same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB0113000D0 GB0113000D0 (en) | 2001-07-18 |
| GB2359561A true GB2359561A (en) | 2001-08-29 |
| GB2359561B GB2359561B (en) | 2004-04-14 |
Family
ID=26579950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB0113000A Expired - Fee Related GB2359561B (en) | 1998-11-27 | 1999-11-26 | LAK activity enhancers derived from extract of Lentinus edodes mycelium and LAKactivity-enhancing formulations containing the extract |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6919081B1 (en) |
| KR (1) | KR20010101065A (en) |
| CN (1) | CN1171630C (en) |
| GB (1) | GB2359561B (en) |
| HK (2) | HK1041435A1 (en) |
| TW (2) | TW200422049A (en) |
| WO (1) | WO2000032212A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11793845B2 (en) | 2016-12-20 | 2023-10-24 | Kinki University | Composition for ameliorating peripheral sensory neuropathy |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO20014256D0 (en) | 2001-09-03 | 2001-09-03 | Bjoern Kristiansen | Preparation of immunostimulatory compound |
| US9072776B2 (en) | 2005-06-15 | 2015-07-07 | Glycanova As | Anti-cancer combination treatment and kit-of-parts |
| CN103285043B (en) * | 2013-05-30 | 2016-01-20 | 北京市农林科学院 | There is the preparation method of the edible fungal protein matter extract of antitumor efficacy |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58118519A (en) * | 1981-12-29 | 1983-07-14 | Noda Shiyokukin Kogyo Kk | Anticancer agent |
| JPH0751511B2 (en) * | 1982-03-15 | 1995-06-05 | 味の素株式会社 | Cancer therapeutic agent containing interleukin-2 |
| JP3017630B2 (en) | 1993-12-17 | 2000-03-13 | 長岡 均 | HIV-type virus activity inhibitor |
| JP2000159686A (en) * | 1998-11-27 | 2000-06-13 | Kobayashi Pharmaceut Co Ltd | Preparation for lak activity potentiation arising from extract from mycelia of lntinus edodes |
-
1999
- 1999-11-26 CN CNB998151874A patent/CN1171630C/en not_active Expired - Fee Related
- 1999-11-26 TW TW093121040A patent/TW200422049A/en unknown
- 1999-11-26 GB GB0113000A patent/GB2359561B/en not_active Expired - Fee Related
- 1999-11-26 US US09/856,718 patent/US6919081B1/en not_active Expired - Fee Related
- 1999-11-26 TW TW088120732A patent/TWI224006B/en active
- 1999-11-26 KR KR1020017006501A patent/KR20010101065A/en not_active Application Discontinuation
- 1999-11-26 WO PCT/JP1999/006616 patent/WO2000032212A1/en not_active Application Discontinuation
-
2002
- 2002-02-27 HK HK02101524.1A patent/HK1041435A1/en unknown
- 2002-06-08 HK HK02104331.8A patent/HK1042651B/en not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| Anticancer Res.,Vol.13,No.5C,1993,Tani,M.et al."Augmentationof...",pp.1773-1776. * |
| Int.J.Immunopharm.,Vol.14,No.4,1992,Arinaga,S.et al., "Enhanced induction...",pp.535-539. * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11793845B2 (en) | 2016-12-20 | 2023-10-24 | Kinki University | Composition for ameliorating peripheral sensory neuropathy |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1171630C (en) | 2004-10-20 |
| HK1042651A1 (en) | 2002-08-23 |
| HK1042651B (en) | 2005-04-22 |
| GB0113000D0 (en) | 2001-07-18 |
| CN1332633A (en) | 2002-01-23 |
| WO2000032212A1 (en) | 2000-06-08 |
| TWI224006B (en) | 2004-11-21 |
| HK1041435A1 (en) | 2002-07-12 |
| GB2359561B (en) | 2004-04-14 |
| TW200422049A (en) | 2004-11-01 |
| KR20010101065A (en) | 2001-11-14 |
| US6919081B1 (en) | 2005-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2003099309A1 (en) | Active fraction having anti-cancer and anti-metastasis isolated from acanthopanax species and fruits | |
| KR20130077802A (en) | The preparing method of immune improving agents | |
| KR102091084B1 (en) | Composition comprising the extract of Molokia leaf for immune activity | |
| Kodama et al. | Potential antitumor activity of a low-molecular-weight protein fraction from Grifola frondosa through enhancement of cytokine production | |
| US6919081B1 (en) | Lak activity potentiator orginating in shitake mushroom hyphae extract and lak activity potentiating preparations containing the same | |
| JP2006124383A (en) | Dendritic cell activator | |
| KR100543354B1 (en) | Herb extract having anti-Hepatitis activity | |
| CA2352614C (en) | Lak activity-screening materials containing lentinus extract of edodes mycelium and lak activity-screening methods using the extract | |
| US20120003262A1 (en) | Anticancer health food containing phellinus linteus and vegetable worms | |
| JP2000159686A (en) | Preparation for lak activity potentiation arising from extract from mycelia of lntinus edodes | |
| US11179425B2 (en) | Method of activating tumor-infiltrating lymphocytes (TILs) | |
| CA2352512A1 (en) | Lak activity enhancers derived from extract of lentinus endodes mycelium and lak activity-enhancers formulations containing the extract | |
| TWI245636B (en) | gamma delta T cell immunoactivity enhancers containing extract of Lentinus edodes mycelium | |
| WO2019209706A2 (en) | Bioactive fungal compounds produced by solid-state fermentation | |
| KR100729213B1 (en) | Exo-biopolymer isolated from submerged mycelial culture of Grifola frondosa increasing immune activity | |
| CN115252657B (en) | Application of Ha Louba dew oral liquid in preparation of anti-tumor products | |
| EP1754473A1 (en) | Antitumor agent | |
| JP4165690B2 (en) | Method for producing interleukin 12 production promoting composition | |
| KR102359433B1 (en) | Cancer vaccine composition and kit | |
| CN111700920A (en) | Physiological function active agent and application thereof | |
| WO2006006272A1 (en) | Dendritic cell activator | |
| JP2006104068A (en) | Dendritic cell-activating agent | |
| JP2000157204A (en) | Fractionated substance of extract from mycelium of lentinus edodes sing. and use thereof | |
| JP2006028070A (en) | Antineoplastic composition | |
| JP2003034648A (en) | Protecting agent for biological membrane |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1041435 Country of ref document: HK |
|
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 20101126 |